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ABSTRACT
Purpose Official guideline of the German Society of Gynecol-
ogy and Obstetrics (DGGG), the Austrian Society of Gynecolo-
gy and Obstetrics (ÖGGG) and the Swiss Society of Gynecolo-
gy and Obstetrics (SGGG). The aim of this guideline was to
standardize the diagnosis and treatment of couples with re-
current miscarriage (RM). Recommendations were based on
the current literature and the views of the involved commit-
tee members.
Methods Based on the current literature, the committee
members developed the statements and recommendations
of this guideline in a formalized process which included DEL-
PHI rounds and a formal consensus meeting.
Recommendations Recommendations for the diagnosis and
treatment of patients with RM were compiled based on the
international literature. Specific established risk factors such
as chromosomal, anatomical, endocrine, hemostatic, psycho-
logical, infectious and immunological disorders were taken in-
to consideration.
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ZUSAMMENFASSUNG
Ziel Offizielle Leitlinie der Deutschen Gesellschaft für Gynäko-
logie und Geburtshilfe (DGGG), der Österreichischen Gesell-
schaft für Gynäkologie und Geburtshilfe (ÖGGG) und der
Schweizerischen Gesellschaft für Gynäkologie und Geburtshil-
fe (SGGG). Ziel der Leitlinie ist es, die Diagnostik und Therapie
des wiederholten Spontanaborts (WSA) anhand der aktuellen
Literatur sowie der Erfahrung der Mitglieder der Leitlinien-
kommission evidenzbasiert zu standardisieren.
Methoden Anhand der internationalen Literatur entwickel-
ten die Mitglieder der beteiligten Fachgesellschaften in einem
formellen Prozess einen Konsensus. Empfehlungen und State-
ments der Leitlinie wurden in einem formalen Prozess (DEL-
PHI-Prozess, Konsenstreffen mit moderiertem Abstimmungs-
prozess) erarbeitet und konsentiert.
Empfehlungen Es wurden Empfehlungen zur Diagnostik und
Therapie von Paaren mit WSA anhand der internationalen Li-
teratur erarbeitet. Insbesondere wurde auf die bekannten
Risikofaktoren wie chromosomale, anatomische, endokrino-
logische, gerinnungsphysiologische, psychologische, infektio-
logische und immunologische Störungen eingegangen.I Guideline Information
Guidelines program of the DGGG, OEGGG and SGGG
Information on the guidelines program is available at the end of
the guideline.
Citation format
Recurrent miscarriage: diagnostic and therapeutic procedures.
Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF
Registry Number 015/050). Geburtsh Frauenheilk 2018; 78:
364–381▶ Table 1 The following professional and scientific societies/working grou
to the compilation of the guideline text and participating in the consensus
conference.
Author/
Mandate holder
Working group/professional societies/or
Lead author and coordinating author:
Prof. Dr. Bettina Toth Austrian Society of Gynecology andObstetri
German Society of Gynecology and Obstetr
German Society for Gynecologic Endocrinol
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Prof. Dr. WolfgangWürfel German Society of Gynecology and Obstetr
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Prof. Dr. M. Bohlmann German Society of Gynecology and Obstetr
Working Group Immunology in the DGGG (A
Prof. Dr. J. Zschocke German Society of Human Genetics (Deutsc
Prof. Dr.
S. Rudnik-Schöneborn
German Society of Human Genetics (GfH)
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Ab antibodies
ANA antinuclear antibodies
aPL antiphospholipid
APS antiphospholipid syndrome
ASA acetylsalicylic acid
ASRM American Society for Reproductive Medicine
FVL factor V Leiden
G‑CSF granulocyte colony-stimulating factor
GM‑CSF granulocyte-macrophage colony-stimulating factor
GW week of gestation
HLA human leukocyte antigen
IVIG intravenous immunoglobulin
LBR live birth rate
LIT lymphocyte immunization therapy
LMWH low-molecular-weight heparin
NK natural killer
PCO polycystic ovaries
PGD preimplantation genetic diagnosis
RCOG Royal College of Obstetricians and Gynaecologists
RM recurrent miscarriage
PT prothrombin
SGA small for gestational age
s/p status post
TPO thyroid peroxidase
TSH thyroid-stimulating hormone
VTE venous thromboembolism▶ Table 2 Grading of recommendations according to the respec-
tive syntax.
Description Syntax
Strong recommendation, strongly binding must
Recommendation, moderately binding should
Open recommendation, not binding mayII Guideline Application
Purpose and objectives
The aim of this guideline is to standardize the diagnosis and treat-
ment of couples with recurrent miscarriage (RM) based on the
most current national and international literature.
Targeted areas of patient care
Outpatient and/or inpatient care.
Target user groups/target audience
The recommendations of the guideline are addressed to gynecol-
ogists and their colleagues working in medical fields such as hu-
man genetics, psychotherapy, laboratory medicine, hemostasis,
internal and general medicine and other professional staff in-
volved in the care of patients with RM. Targeted patient group:
couples with RM
Adoption of the guideline and period of validity
The validity of this guideline was confirmed by the respective
boards/representatives of the participating professional medical
societies, working groups, organizations and associations, by the
board of the DGGG, SGGG and OEGGG and the DGGG/OEGGG/
SGGG Guideline Commission in January 2018 and thereby ap-
proved in its entirety. This guideline is valid from February 1,
2018 through to January 31, 2021. The above-mentioned period
of validity is only an estimate. The guideline can be updated ear-
lier if urgently required. Should the guideline continue to reflect366the current level of scientific knowledge, then the guidelineʼs pe-
riod of validity can be extended.III Methodology
Basic principles
Because of the complex biological processes which occur in the
context of RM and the heterogeneity of the studies published on
this topic, there is widespread uncertainty about the optimal indi-
vidual diagnosis and therapy of women with RM. An updated S2k-
level guideline was therefore considered advisable to improve the
quality of care. The guideline aims to provide information and ad-
vice for women with RM about appropriate diagnostic procedures
and evidence-based treatment strategies. In addition, the recom-
mendations of the guideline should serve as the basis for interdis-
ciplinary decision-making.
This guideline is based on the S1 guideline “Recurrent Miscar-
riage: Diagnostic and Therapeutic Procedures” (AWMF 015/050),
published in 2013, and the results of a recent literature search (as
per September 2017). The relevant literature was assigned to the
various chapters with the help of degree candidate Eva Preisl and
Dr. Katharina Feil, both from the University Hospital for Gyneco-
logical Endocrinology and Reproductive Medicine, Innsbruck, Aus-
tria. A coherent draft version was compiled from the individual
chapters, which was edited in a joint advance consensus. State-
ments and recommendations which took the form of unambigu-
ous instructions were then extracted from the draft text. The re-
vised text was subsequently circulated among all the member of
the guideline commission. The members proposed changes to the
text and voted on the final manuscript.
This guideline is classified as: S2k
Grading of recommendations
As no systematic search, selection, evaluation and synthesis of the
evidence base was carried out, the guideline does not discuss lev-
els of evidence. The recommendations are graded as follows
(▶ Table 2):Statements
Expert statements included in this guideline which are not recom-
mendations for action but are simple statements of fact are refer-
red to as “Statements”. It is not possible to provide a level of evi-
dence for these statements.Toth B et al. Recurrent Miscarriage: Diagnostic… Geburtsh Frauenheilk 2018; 78: 364–381
Achieving consensus and level of consensus
An interdisciplinary group voted on the statements and recom-
mendations at three consensus conferences. The statements and
recommendations of the guideline were discussed at consensus
conferences held on 20th April 2017, 6th June 2017 and 19th Sep-
tember 2017 in Munich. Following a moderated formal consensus
process, the participants of the conferences jointly consented to
the statements and recommendations. The consent protocol is
available on request.
During the compilation of this guideline, special consideration
was given to existing recommendations (the guideline was first
compiled in 2006 and revised in 2008 and 2013), the recommen-
dations of the European Society of Human Reproduction and Em-
bryology (ESHRE 2017), the Royal College of Obstetricians and
Gynecologists [1], the American College of Obstetricians and
Gynecologists (ACOG 2002) [2] and the American Society for Re-
productive Medicine (ASRM 2012) [3].
During structured consensus-based decision-making (S2k/S3
level), authorized participants present at a session vote on draft
Statements and Recommendations. Discussions during sessions
may lead to significant changes in the wording of Statements
and Recommendations, etc. The extent of agreement, which de-
pends on the number of participants, is determined at the end of
the session (▶ Table 3).▶ Table 3 Classification of extent of agreement in consensus deci-
sion-making.
Symbol Level of consensus Extent of agreement
in percent
+++ Strong consensus > 95% of participants agree
++ Consensus > 75–95% of participants agree
+ Majority agreement > 50–75% of participants agree
– No consensus < 50% of participants agreeExpert consensus
As the name implies, this refers to consensus decisions taken with
regard to specific Recommendations/Statements without a pre-
vious systematic search of the literature (S2k) or when evidence
is lacking (S2e/S3). The term “Expert Consensus” (EC) used here▶ Table 4 Probability of recurrent miscarriage depending on maternal age
Andersen et al. [9].
Previous miscarriages Risk of recurrence
25–29 years 30–34 years
1miscarriage ~ 15% ~ 16–18%
2miscarriages ~ 22–24% ~ 23–26%
≥ 3 miscarriages ~ 40–42% ~ 38–40%
Toth B et al. Recurrent Miscarriage: Diagnostic… Geburtsh Frauenheilk 2018; 78: 364–381is synonymous with terms such as “Good Clinical Practice” (GCP)
or “Clinical Consensus Point” (CPP) used in other guidelines. The
level of recommendation is graded as previously described in the
Chapter “Grading of recommendations” but only semantically
(“must/must not” or “should/should not” or “may/may not”) and
without using the symbols shown there.IV Guideline
1 Introduction
Counselling and treating couples with RM is a diagnostic and ther-
apeutic challenge as several possible causes for RM are known,
but no risk factor for RM is identified in the majority of affected
patients.
2 Incidence and Definition
Approximately 1–3% of all couples of reproductive age experience
recurrent miscarriage [4]. A miscarriage is defined as the loss of a
fetus at any time between conception and the 24th week of ges-
tation (GW) or the loss of a fetus weighing < 500 g [5]. The World
Health Organization (WHO) definition of recurrent spontaneous
miscarriage is: “three and more consecutive miscarriages before
the 20th GW” [5]. The American Society for Reproductive Medi-
cine (ASRM) already defines the occurrence of two consecutive
miscarriages as RM [3,6]. This definition increases the incidence
of RM to 5% of all couples of reproductive age [7]. This guideline
takes the WHO definition (≥ 3 consecutive recurrent miscarriages)
as the basis for its recommendations on diagnostic and therapeu-
tic procedures.
If a woman has not previously given birth to a live infant, the
loss of the fetus is referred to as primary RM; if the woman has
had a previous live birth, the pregnancy loss is referred to as sec-
ondary RM [8]. Another classification, which refers to the course
of the miscarriages, classifies miscarriages into repeated loss of
embryonic pregnancy (sporadic loss) or loss of fetal pregnancy
(detectable heart beat on sonography or histologically verifiable
embryo) [3].
The risk of recurrent miscarriage varies significantly, depend-
ing on a number of different factors. In addition to maternal age,
the number of previous miscarriages also affects the risk of recur-
rence. ▶ Table 4 presents the data from a retrospective registry
study [9].and the number of previous miscarriages, based on the study of Nybo-
35–39 years 40–44 years
~ 21–23% ~ 40%
~ 25–30% ~ 40–44%
~ 40–45% ~ 60–65%
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Consensus-based Recommendation 3-2.E1
Expert consensus Level of consensus ++
Cytogenetic analysis must be done if a woman experiences recurrent mis-
carriages. This can be done either by chromosome analysis of both partners
prior to conception or using tissue samples from themiscarried fetus.
Consensus-based Recommendation 3-2.E2
Expert consensus Level of consensus +++
Both partners must undergo cytogenetic testing if a structural chromo-
somal disorder is detected in the tissue of the miscarried fetus. The couple
must be informed of the findings during genetic counselling carried out by
a specialist for human genetics or a physician with the relevant qualifica-
tions in accordance with national legal regulations.
Consensus-based Statement 3-2.S1
Expert consensus Level of consensus ++
If a balanced chromosomal aberration is detected in one of the parents, the
risk of miscarriage or of giving birth to an infant with a chromosomal disor-
der increases, depending on the chromosomes involved. This will affect
antenatal diagnostic procedures in any further pregnancies.
GebFra Science | Guideline3 Diagnosis and Treatment of Relevant
Risk Factors
3.1 Lifestyle and behavior
3.1.1 Stress
Some studies have indicated that higher stress levels during preg-
nancy might be associated with an increased risk of pregnancy
loss. A case-control study of 45 patients with RM concluded that
stress levels were higher compared to 40 control patients [10]. A
study of 301 patients with RM (defined as ≥ 3 miscarriages) com-
pared to women wanting to children reported similar findings
[11]. Because of the small number of cases, it is not possible,
based on the currently available data, to conclude that stress in-
creases the risk of miscarriage.
3.1.2 Coffee consumption
A few observational studies have reported a dose-dependent rela-
tionship between coffee intake and late loss of pregnancy [12]. A
larger case-control study was also able to show that coffee con-
sumption had an impact on early miscarriage [13]. Another retro-
spective case-control study demonstrated a significantly in-
creased risk of RM following coffee consumption in the pericon-
ceptional period and in early pregnancy. It was not possible to
show a linear association between the amount of coffee con-
sumed and the risk of RM [14].
3.1.3 Nicotine and alcohol consumption
There is a strong association between nicotine consumption and
poor obstetric and neonatal outcomes such as ectopic pregnancy,
stillbirth, placenta previa, premature birth, low birthweight and
congenital malformation. Cessation of smoking should therefore
be recommended to all pregnant women [15]. The impact of
smoking and of cessation of smoking on the risk of RM is not clear.
A retrospective study compared 326 patients with RM with 400
control patients who had had at least one live birth. The study
showed that even passive smoking significantly increased the risk
of RM [16]. Another study came to the conclusion that maternal
nicotine, alcohol or coffee consumption was not associated with
a higher probability of RM [17].
A prospective study, which evaluated the impact of paternal
smoking on the risk of miscarriage, investigated 526 couples and
was able to show that women who were heavy smokers (> 20 cig-
arettes per day) had a higher risk of early miscarriage. Heavy
smoking (more than 20 cigarettes per day) had a significantly
greater impact than moderate smoking (< 20 cigarettes per day)
[18]. There are currently no studies on the impact of smoking ces-
sation on the chances of giving birth to a live infant for couples
with RM.
3.2 Genetic factors
3.2.1 Chromosomal anomalies
Embryonic/fetal chromosomal abnormalities are the most com-
mon cause of spontaneous miscarriage [19,20]. The earlier the
miscarriage occurs, the more likely that an embryonic/fetal chro-
mosomal anomaly was present [21]. The risk of embryonic/fetal
trisomy resulting from chromosomal aberrations increases with
higher maternal age. The most common cause of miscarriage is
trisomy 16, followed by trisomy 22. Triploidy was detected in ap-368proximately 15% of cytogenetically abnormal fetuses. Monosomy
X is responsible for approximately 20% of miscarriages which oc-
cur in the first trimester of pregnancy. No association with mater-
nal age has been found for monosomy X, polyploidy or structural
chromosomal disorders [22]. A balanced chromosomal abnormal-
ity in one of the partners was confirmed in around 4–5% of cou-
ples who had 2 or more miscarriages [23]. In around 1% of preg-
nancies, an unbalanced set of chromosomes was detected during
prenatal diagnostic procedures or after the birth [24,25].It is not possible to carry out standard chromosomal analysis in
around 18% of miscarried fetuses, and array analysis cannot be
done in around 5% of miscarried fetuses [26]. Overall, molecular
cytogenetic analysis only detected additional chromosomal dis-
orders in around 5% of cases, and the routine use of array analysis
to identify the cause of miscarriage is therefore not useful at
present [26].3.2.2 Monogenetic disease
X-linked dominant disorders that are lethal in males have an in-
creased risk of miscarriage. But autosomal dominant and reces-
sive disorders with severe malformations can also result in in-
creased intrauterine mortality. In these cases, examination of the
fetus should include genetic and pathological testing, particularly
if the disorder was not identified prenatally.Toth B et al. Recurrent Miscarriage: Diagnostic… Geburtsh Frauenheilk 2018; 78: 364–381
Consensus-based Recommendation 3-2.E3
Expert consensus Level of consensus ++
If there are indications that monogenetic disease may be the cause of mis-
carriage, genetic counselling must include genetic testing.3.2.3 Results of association studies
Numerous studies suggest possible maternal, paternal or fetal ge-
netic effects, but these appear to have very little impact on the
risk of miscarriage [27].Consensus-based Recommendation 3-2.E4
Expert consensus Level of consensus +++
Molecular genetic analysis for gene variants detected in association studies
is not recommended for couples with RM.
Consensus-based Recommendation 3-3.E6
Expert consensus Level of consensus +++
Vaginal sonography and/or hysteroscopy is recommended in women with3.2.5 Therapeutic options
It is not possible to treat the causes of chromosomal disorders.
Previous studies have not shown that PGD after IVF results in an
increased rate of live births in women with RM compared to spon-
taneous pregnancies, not even for couples who are genetically at
risk because one partner has a balanced chromosomal aberration.
Neither the ESHRE and RCOG guidelines nor the ASRM Statement
recommend preimplantation genetic diagnosis for couples with
RM.Consensus-based Recommendation 3-2.E5
Expert consensus Level of consensus +++
Preimplantation genetic diagnosis to prevent miscarriage is not recom-
mended for couples with RMwho have no familial chromosomal disorder
and no monogenetic disease.
RM to rule out uterine malformations, submucosal uterine fibroids and
polyps. Hysteroscopy is recommended to rule out intrauterine adhesions.
Consensus-based Recommendation 3-3.E7
Expert consensus Level of consensus +++
Hysteroscopic septum resection is recommended to treat women with RM
and septate uterus.3.3 Anatomical factors
3.3.1 Diagnosis of anatomical factors
3.3.1.1 Congenital malformations
Hysteroscopic examinations of patients who had 2, 3 and ≥ 4 con-
secutive miscarriages found no difference in the prevalence of
congenital (uterine malformations) or acquired (adhesions,
polyps, submucosal fibroids) intrauterine pathologies [28]. The in-
creased probability of miscarriage in women with subseptate
uterus is well known, but the cause of this association is unknown
[29]. It is not clear whether there is an association between RM
and other uterine malformations such as arcuate uterus or bicorn-
uate uterus. Ludwin et al. [30] reported significantly better diag-
nostic results when using sonohysterography (SHG) to diagnose
congenital uterine malformations compared with hysterosalpin-
gography (HSG) or hysteroscopy. But it is difficult to evaluate
statements comparing diagnostic methods, because even when
hysteroscopy videos were presented to experienced international
observers, interobserver agreement was found to be poor [31].Toth B et al. Recurrent Miscarriage: Diagnostic… Geburtsh Frauenheilk 2018; 78: 364–381When diagnosing uterine malformations, the decision whether
to use hysteroscopy – possibly in combination with laparoscopy
or 3D sonography – must be made on an individual basis [32].
3D sonography is recommended for the diagnostic workup of
uterine malformations in high-risk populations and MRI and endo-
scopic examinations are recommended for diagnostic problems
or suspected complex malformations [33].
3.3.1.2 Acquired malformations
Although the study populations consisted only of women under-
going IVF, a meta-analysis of 19 observational studies showed a
higher but not statistically significant rate of miscarriages in wom-
en with intramural fibroids and no submucosal involvement (rela-
tive risk [RR] 1.24; 95% CI: 0.99–1.57) [34]. In an evaluation of ret-
rospective and prospective data of patients with RM, the inci-
dence of submucosal fibroids was 2.6% (25/966) [35]. These
study data suggest an association between submucosal fibroids
and the occurrence of miscarriage, but the quality of the data is
poor. A Cochrane analysis which only included a few studies
showed no significant reduction in the risk of miscarriage after
uterine fibroids had been resected (intramural: OR 0.89, 95% CI:
0.14–5.48; submucosal: OR 0.63, 95% CI: 0.09–4.40) [36].
It is not clear whether – as with submucosal fibroids – intraca-
vitary polyps also increase the risk of miscarriage.3.3.2 Treatment for anatomical factors
Hysteroscopic septum dissection is recommended for women
with RM and septate uterus [37]. A meta-analysis carried out in
2017 showed that no randomized studies on the therapeutic ef-
fect of septum dissection have been carried out to date [38]. But
retrospective uncontrolled studies suggest that the surgical inter-
vention is beneficial. Postoperative healing takes about 2 months
[39], and there are no reasons to avoid pregnancy thereafter. Sur-
gical intervention is not indicated for other uterine malformations
such as bicornuate uterus, uterus didelphys and arcuate uterus
[40–42].369
Consensus-based Recommendation 3-4.E12
Expert consensus Level of consensus ++
An endometrial biopsy may be performed in women with RM to rule out
chronic endometritis (supported by immunohistochemical staining for the
GebFra Science | GuidelineHysteroscopic adhesiolysis is the therapy of choice to treat in-
trauterine adhesions [43]. It is not clear whether or to what extent
intrauterine adhesions affect the risk of miscarriage and whether
adhesiolysis will reduce the risk of RM.Consensus-based Recommendation 3-3.E8
Expert consensus Level of consensus ++
Hysteroscopic adhesiolysis is recommended to treat women with RM and
intrauterine adhesions.
plasma cell surface antigen CD138).There are no randomized studies on the therapeutic benefits of
fibroid resection in women with RM.Consensus-based Recommendation 3-3.E9
Expert consensus Level of consensus ++
Surgical resection should be performed inwomenwith RMand submucosal
fibroids.
Consensus-based Recommendation 3-4.E13
Expert consensus Level of consensus ++
Antibiotic therapy may be administered to women with RM and chronic
endometritis to prevent miscarriage.A meta-analysis showed that hysteroscopic resection of intra-
uterine polyps visible on ultrasound carried out before intrauter-
ine insemination can increase clinical pregnancy rates [44]. The
resection of persistent polyps can be considered if there is no oth-
er explanation for RM.Consensus-based Recommendation 3-3.E10
Expert consensus Level of consensus ++
Hysteroscopic resection should be carried out to prevent miscarriage in
women with RM and persistent polyps.
Consensus-based Recommendation 3-5.E14
Expert consensus Level of consensus ++
An endocrine workup determining TSH levels is recommended in women
with RM. If TSH levels are found to be abnormal, fT3, fT4 and thyroid hor-
mone autoantibody concentrations must also be determined.3.4 Microbiological factors
3.4.1 Diagnostic workup of microbiological factors
Because the association between infections and RM is unclear,
general screening for vaginal infections which goes beyond the
routine screening carried out as part of prenatal care is not recom-
mended. However, chronic endometritis, as evidenced by the
finding of plasma cells in the endometrial biopsy, was detected in
7–67% of otherwise asymptomatic women with RM and in 30–
66% of women with recurrent implantation failure [45–49]. En-
dometrial biopsy may be performed in women with RM to exclude
chronic endometritis (supported by immunohistochemical stain-
ing for the plasma cell surface antigen CD138).Consensus-based Recommendation 3-4.E11
Expert consensus Level of consensus +++
Infectious screening using vaginal swab specimens is not recommended in
asymptomatic women with RM.
3703.4.2 Treatment for microbiological factors
Pregnant women suspected of having a vaginal infection should
receive proper testing and treatment [50,51]. Antibiotic therapy
with doxycycline (e.g. 200mg 1–0–0 for 14 days) is indicated for
chronic endometritis; in the event of persistent endometritis as
evidenced by the persistence of plasma cells, treatment can con-
sist of ciprofloxacin with/without metronidazole [45].3.5 Endocrine factors
3.5.1 Diagnostic workup of endocrine factors
According to a retrospective analysis, manifest hyperthyroidism is
associated with increased miscarriage rates [52]. This also applies
to manifest hypothyroidism. It is still unclear, however, whether
latent hypothyroidism (i.e. increases in TSH concentrations de-
spite thyroid hormone concentrations within normal ranges) also
increases the risk of miscarriage. A meta-analysis of two studies
reported that the LBR was not lower for women with RM and
TSH concentrations of > 2.5mU/L [53]. Increased levels of thyroid
hormone autoantibodies appear to be associated with higher
rates of spontaneous miscarriage [54]. PCOS, hyperandrogenemia
(which is often PCOS-related [55]), insulin resistance [56,57] and
diabetes [58] are all associated with a higher tendency to mis-
carry. PCOS per se is not a predictive factor for miscarriage or RM
[59], whereas obesity per se appears to increase the rate of mis-
carriages.Consensus-based Recommendation 3-5.E15
Expert consensus Level of consensus +++
The BMI of women with RM should be determined. Women with a BMI
≥ 30 kg/m2may be investigated further to determine whether they have a
metabolic syndrome.
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Consensus-based Recommendation 3-6.E19
Expert consensus Level of consensus +++
Women with a prior history of mental illness, women who are involuntarily
childless, and women who lack or have only limited social resources or are
struggling with feelings of guilt related to processing their experience of
RMmust be given information about psychosocial assistance and support
(including self-help groups and internet forums).
Consensus-based Recommendation 3-6.E20
Expert consensus Level of consensus +++
A psychotherapist must be called in if there is a suspicion that the patient is3.5.2 Treatment for endocrine factors
It is important to diagnose and treat manifest hyperthyroidism or
hypothyroidism. A meta-analysis of studies of IVF patients with in-
creased levels of thyroid hormone autoantibodies (RM was no in-
clusion criterion) and pregnant women with higher levels of TPO
antibodies showed that substitution of thyroid hormones de-
creased the rate of miscarriages [54]. No statement was made
about the rate of live births. However, other studies such as the
study by Negro et al. published in 2016 [60] were unable to dem-
onstrate the effect. It is therefore possible that patients with RM
and TPO autoantibodies benefit from the substitution of thyroid
hormones in terms of a lower rate of miscarriages, but currently
there is no data specifically on patients with RM.Consensus-based Recommendation 3-5.E16
Expert consensus Level of consensus +++
Manifest hypothyroidism or hyperthyroidismmust be treated before con-
ception.
Consensus-based Recommendation 3-5.E17
Expert consensus Level of consensus ++
Thyroid hormone substitution therapy can be administered to prevent
miscarriage in women with RM and latent hypothyroidism, i.e. patholog-
ically increased TSH concentrations despite fT3 and fT4 concentrations
within normal ranges or the presence of TPO autoantibodies.
suffering from reactive depression following RM to determine whether the
affected patient/couple require(s) further treatment.
Consensus-based Statement 3-6.S2
Expert consensus Level of consensus +++
The efficacy of “tender loving care” as a therapeutic intervention to prevent
miscarriage in women with RM is not proven. However, tender loving care
can provide psychological support.A meta-analysis found that the administration of metformin
had no effect on the risk of sporadic miscarriage [61], and the
guideline can therefore not make any recommendation regarding
the administration of metformin.
There are many medical reasons why women with a high BMI
should lose weight (cf. the S3 guideline on “Gestational Diabetes”,
AWMF guideline 057/008). A Danish cohort study [62] showed
that the risk of miscarriage increases for women with a BMI
≥ 30 kg/m2 (OR 1.23; 95% CI: 0.98–1.54).Consensus-based Recommendation 3-5.E18
Expert consensus Level of consensus +++
Women with RM and a high bodymass index should be encouraged to lose
weight.
Consensus-based Recommendation 3-7.E21
Expert consensus Level of consensus ++
Alloimmune investigations such as determining the Th1/Th2 ratio or the
T4/T8 index, analysis of pNK and/or uNK cells, NK toxicity tests, lymphocyte
function tests, molecular genetic testing for non-classical HLA groups (Ib)
or KIR receptor families and determination of HLA should not be done in
women with RM outside clinical studies, unless there is evidence of a pre-
existing autoimmune disorder.3.6 Psychological factors
Evidence-based medicine has not been able to show that RM can
be directly caused by psychological factors such as stress alone
[10,63,64].Toth B et al. Recurrent Miscarriage: Diagnostic… Geburtsh Frauenheilk 2018; 78: 364–3813.7 Immunological factors
3.7.1 Diagnosis of immunological factors
3.7.1.1 Alloimmune factors
Activation of the immune system (particularly of the Th1 re-
sponse) results in unfavorable conditions for implantation and is
associated with an increased probability of RM [51,65–69]. It
has not yet been clearly proven that an increase in the Th1/Th2
ratio or T4/T8 index leads to an increased risk of miscarriage [51,
66,70–73]. Several studies have pointed to an increase in natural
killer cells in peripheral blood (pNK cells) in patients with RM com-
pared to healthy controls [74–77]. Recent studies have also
pointed to a significant increase in uterine natural killer cells
(uNK cells) in patients with idiopathic RM [78,79].3.7.1.2 Autoimmune factors
Although the data are not consistent, the majority of studies re-
port increased ANA titer levels in women with RM [80–86]. Celiac
disease is characterized by gluten sensitivity; its association with
RM is still controversially discussed. Testing for immunoglobulin371
Clinical criteria
Laboratory criteria (detected on 2 separate occasions
at an interval of 12 weeks)
≥1 venous or arterial thrombosis
Anti-cardiolipin antibodies (IgM, IgG) –
moderate to high titer
1 or 2 unexplained miscarriages of morphologically
normal fetuses after the 10th GW, 3 miscarriages
before the 10th GW
≥
Anti- 2 glycoprotein 1 antibodies (IgM, IgG) –
high titer
β
Lupus anticoagulant
≥1 late miscarriage or preterm birth before the 34th
GW because of placental insufficiency or preeclampsia
▶ Fig. 1 Diagnostic criteria for antiphospholipid syndrome [89].
Clinical and laboratory criteria can be present either in combination
or singly. By definition, however, at least one clinical and one labora-
tory criterion must be present to make a diagnosis of antiphospho-
GebFra Science | GuidelineA (IgA) antibodies against tissue transglutaminase can be done in
women with a history of food sensitivity (food intolerances, irreg-
ular bowel motions) and RM, followed by biopsy of the small intes-
tine if the findings are positive [87].
Testing for antiphospholipid syndrome using clinical and labo-
ratory parameters is recommended in women with RM (▶ Fig. 1).
Non-specific antibodies against anionic phospholipids such as car-
diolipins and β2 glycoproteins, also known as antiphospholipid
antibodies (aPLAb) have been detected in some women with RM.
However, according to the definition given in ▶ Fig. 1, antiphos-
pholipid (aPL) syndrome is only present if both clinical and labora-
tory criteria are fulfilled. Between 2% and 15% of women with RM
suffer from aPL syndrome [88]. During the diagnostic workup, it is
important to determine whether aPL antibody titer is still moder-
ate to high at the 12-week follow-up after first determining the
titer, i.e., whether it is in the > 99th percentile compared to unre-
markable controls [89].
A few studies have considered the possibility of so-called
“non-criteria” aPL syndrome, particularly when manifestations
(livedo reticularis, ulcerations, renal microangiopathies, neuro-
logical disorders and cardiac manifestations) are present and the
diagnostic criteria for classic aPL syndrome are not fulfilled or only
in part (e.g., low aPLAb titer or s/p 2 miscarriages) [89].Consensus-based Recommendation 3-7.E22
Expert consensus Level of consensus +++
Testing for antiphospholipid syndrome based on clinical and laboratory
parameters (▶ Fig. 1) is recommended for women with RM.
Consensus-based Recommendation 3-7.E23
Expert consensus Level of consensus +++
Interdisciplinary care must be offered to women with RM and an auto-
immune disease already present prior to conception.
Consensus-based Recommendation 3-7.E24
Expert consensus Level of consensus ++
Testing for non-criteria antiphospholipid syndrome based on clinical and
laboratory parameters should be done in women with RM, particularly if
clinical manifestations are present (livedo reticularis, ulcerations, renal mi-
croangiopathies, neurological disorders and cardiac manifestations).
Consensus-based Recommendation 3-7.E25
Expert consensus Level of consensus ++
Glucocorticoids must not be administered outside clinical studies as pro-
phylaxis to preventmiscarriage in womenwith RM but without pre-existing
autoimmune disease.
lipid syndrome. [rerif]3.7.2 Treatment for immunological factors
3.7.2.1 Glucocorticoids
The results of existing clinical studies which administered gluco-
corticoids to women with RM are inconsistent [90–93]. Treat-
ment with glucocorticoids – particularly at higher doses – can in-
duce side effects such as gestational diabetes, arterial hyperten-
sion, preterm birth, low birthweight (SGA) and disorders of neuro-
logical development in the infant [94–96]. This type of treatment372should therefore be reserved for patients with pre-existing auto-
immune diseases which require therapy with glucocorticoids even
during pregnancy.3.7.2.2 Intravenous immunoglobulins
A few studies have pointed out that intravenous administration of
immunoglobulins (IVIG) reduces the concentrations and activities
of natural killer cells in peripheral blood and affects Th1-mediated
immune response [97]. The studies were very heterogeneous and
the majority were done in patients with idiopathic RM but without
a specific immunological diagnostic workup prior to starting ther-
apy. The data is inconsistent [97–100].
A recent meta-analysis which included 11 randomized studies
of the type described above found no significantly higher LBR for
the group of patients who received IVIG (RR 0.92; 95% CI: 0.75–
1.12) compared to placebo or standard care [101]. A subgroup
analysis showed a trend towards a benefit from IVIG in the cohort
of patients with secondary RM compared to placebo (RR for no
live births 0.77; 95% CI: 0.58–1.02; p = 0.06). There are currently
no clearly defined indications for the administration of immuno-
globulins, and they should therefore not be administered outsideToth B et al. Recurrent Miscarriage: Diagnostic… Geburtsh Frauenheilk 2018; 78: 364–381
Consensus-based Recommendation 3-7.E28
Expert consensus Level of consensus +
Allogeneic lymphocyte transfer to prevent miscarriage should not be
carried out in women with RM outside clinical studies.clinical studies. Side effects which can even include anaphylactic
shock and the transmission of infectious pathogens are rare, but
the incidence of occurrence is significantly higher in the verum
group compared to controls.Consensus-based Recommendation 3-7.E26
Expert consensus Level of consensus ++
Therapy with intravenous immunoglobulins to prevent miscarriage should
not be given to women with RM outside clinical studies.
Consensus-based Recommendation 3-7.E29
Expert consensus Level of consensus ++
Therapy with TNF-α receptor blockers should not be given to women with
RM outside clinical studies.3.7.2.3 Lipid infusion
Current studies showed that soybean-oil-based lipid infusions re-
duced both NK cell activity and the formation of pro-inflamma-
tory cytokines [102–106]. Small observational studies have
shown that lipid infusions administered to women with RM or im-
plantation failure and increased NK cell activity achieved the same
live birth rates as treatment with IVIG [107–109]. A randomized
placebo-controlled double-blind study carried out in Egypt inves-
tigated the impact of a single lipid infusion in a cohort von 296
women (with no tubal pathology and aged less than 40 years)
undergoing IVF. The investigated women all had ≥ 3 idiopathic
RM (consecutive clinical miscarriages after spontaneous concep-
tion or IVF/ICSI) and had elevated levels of peripheral blood NK
cells (pNK cells > 12%) [110]. No significant difference in the rate
of biochemical pregnancies was found between groups, but the
rate of intact pregnancies > 12th GW and the rate of live births
(37.5 vs. 22.4%, respectively; p = 0.005) was significantly higher
in the group which had received a lipid infusion.Consensus-based Recommendation 3-7.E27
Expert consensus Level of consensus +++
Lipid infusion to preventmiscarriage should not be administered to women
with RM outside clinical studies.3.7.2.4 Allogeneic lymphocyte transfer (LIT)
The transfer of allogeneic lymphocytes (usually paternal lympho-
cytes, rarely donor lymphocytes, also known as lymphocyte im-
munization therapy) is a means of readying the maternal immune
system to cope with the embryoʼs foreign antigens (HLA). The da-
ta on the uses of this therapy in women with RM is inconsistent.
Two recent meta-analyses pointed to higher LBR in patients with
idiopathic RM who received LIT. However, these meta-analyses
were strongly influenced by the weighting of an Asian study, pub-
lished in 2013, which showed a positive effect [111–113]. Older
studies found no benefit [114–116], meaning that, here too, fur-
ther studies will be necessary. It should be noted that the transfu-
sion of blood products can lead to complications (e.g., transmis-
sion of infections, formation of irregular autoantibodies, induc-
tion of autoimmune disorders).Toth B et al. Recurrent Miscarriage: Diagnostic… Geburtsh Frauenheilk 2018; 78: 364–3813.7.2.5 TNF-α receptor blockers
Subgroups of patients with RM have been reported to have in-
creased TNF-α concentrations, abnormal TNF-α/IL‑10 ratios or
numbers of TNF-α-producing CD3+CD4+ lymphocytes, and these
subgroups could benefit from the administration of TNF-α recep-
tor blockers (e.g., adalimumab or infliximab) [100,117]. However,
only one retrospective study has looked at this issue to date. In ad-
dition to TNF-α receptor blockers, the study also used low-dose
acetylsalicylic acid (ASA), low-molecular-weight heparin (LMWH)
and immunoglobulins [100]. Well-known side effects ranged from
skin reactions to infections and even rare adverse events such as
drug-induced lupus [118]. There are also concerns regarding the
possible induction of malignant disease by TNF-α blockers [119].
At present, the administration of TNF-α receptor blockers should
be reserved for controlled clinical studies and for specific condi-
tions (e.g., autoimmune diseases such as Crohnʼs disease or
chronic polyarthritis).3.7.2.6 Treatment for autoimmune factors
Because of the inconsistent data on the prevalence of antinuclear
antibodies in women with RM, the current therapy strategies
(ASA, glucocorticoids, low-molecular-weight heparin) are incon-
sistent and the guideline cannot offer any recommendations.
There is currently only one retrospective study on the therapy of
women with celiac disease and RM (n = 13) [120]. The women in
the study benefitted from a gluten-free diet.
Therapy with low-dose acetylsalicylic acid and low-molecular-
weight heparin is recommended for women with RM and anti-
phospholipid syndrome. Treatment with acetylsalicylic acid and
heparin must be initiated as soon as the pregnancy test is positive.
Aspirin administration must continue until GW 34 + 0, with hepa-
rin administration continuing for at least 6 weeks post partum.
Numerous studies have shown that patients with RM and APS
benefited from the administration of aspirin (50–100mg/d) and
low-molecular-weight heparin in prophylactic doses [121–125].
In contrast to the administration of LMWH and aspirin, other ther-
apeutic approaches such as the administration of corticoids, im-
munoglobulins or aspirin alone did not result in any significant im-
provement in the LBR of patients with RM and APS [121].
Based on current studies, non-criteria aPL syndrome should be
treated in exactly the same way, as a few studies have indicated a373
Consensus-based Recommendation 3-8.E33
Expert consensus Level of consensus +++
GebFra Science | Guidelinepotential benefit from the administration of LMWH in combina-
tion with ASA [126–130].Consensus-based Recommendation 3-7.E30
Expert consensus Level of consensus +++
Therapy with low-dose acetylsalicylic acid and low-molecular-weight hep-
arin is recommended for women with RM and antiphospholipid syndrome.
Treatment with acetylsalicylic acid and heparin must be initiated as soon as
the pregnancy test is positive. Aspirin administration must continue until
GW34 + 0, with heparin administration continuing for at least 6 weeks post
partum.
Consensus-based Recommendation 3-7.E31
Expert consensus Level of consensus +++
Therapy with low-dose acetylsalicylic acid and low-molecular-weight hep-
arin is recommended for womenwith RM andnon-criteria antiphospholipid
syndrome. Treatment with acetylsalicylic acid and heparinmust be initiated
as soon as the pregnancy test is positive. Aspirin administration must con-
tinue until GW 34 + 0, with heparin administration continuing for at least
6 weeks post partum.
Women with RM who are at risk of thromboembolic events must be tested
for thrombophilia. This includes determination of antithrombin activity and
plasma protein C and protein S levels and molecular genetic analysis for
factor V Leiden mutation and prothrombin G20210Amutation.
Consensus-based Recommendation 3-8.E34
Expert consensus Level of consensus ++
Treatment with heparin with the sole purpose of preventing miscarriage
is not recommended for women with RM. This also applies to women with3.8 Coagulation
3.8.1 Diagnosis of congenital thrombophilic factors
Hereditary thrombophilic parameters are present in up to 15% of
the Caucasian population [131]. In recent years, the assessment
of maternal thrombophilia as an important risk factor for RM has
significantly changed. Thrombophilia testing done only to prevent
miscarriage is not recommended. International guidelines (ASRM,
ACCP, RCOG) do not recommend routine testing for hereditary
thrombophilia in women with RM [1,3,132–134]. The RCOG
guideline considers testing for maternal hereditary thrombophilia
to be only indicated in the context of scientific studies [133]. The
ASRM recommendations propose thrombophilia testing for wom-
en with RM only if they have a medical or familial history of throm-
boembolic events [1,3, 132–134].
Abnormalities in thrombophilic parameters may be an indica-
tion to treat pregnant women for medical reasons (prevention of
thrombembolic events). Anticoagulation therapy to prevent ma-
ternal thromboembolism may be justified in pregnant women
who have an increased risk of thromboembolic events (VTE) due
to specific conditions (e.g., antithrombin deficiency, homozygous
FVL mutation, combined heterozygous FVL and PT mutation, etc.)
and in women with additional risk factors for VTE in pregnancy
(immobilization, surgery, excessive weight gain, etc.) (ACOG
2013, AWMF 2015).Consensus-based Recommendation 3-8.E32
Expert consensus Level of consensus ++
Testing for thrombophilia to prevent miscarriage is not recommended.
3743.8.2 Treatment for women at risk
of thrombophilic events
3.8.2.1 Heparin
Unfractionated and low-molecular-weight heparins differ with re-
gard to their molecular weight, plasma protein binding, biological
half-life and rate of side effects. In addition to their anticoagula-
tion effect, they also have numerous effects at the molecular level
of the embryo-maternal interface which are still not completely
understood [135]. No heparins cross the placenta. The adminis-
tration of low-molecular-weight heparin(s) during pregnancy is
considered comparatively safe [136]. The administration of hepa-
rins in pregnancy represents an off-label use. If the administration
of heparin in pregnancy is indicated, low-molecular-weight hepa-
rins should be used because of their superior side-effects profile
and ease of administration [132]. The enthusiasm at the turn of
the century about the impact of prophylactic heparin administra-
tion in women with RM (in whom APS had been excluded) on the
prevention of miscarriage could not be confirmed in either large
prospective randomized studies [137–139] or in more recent
meta-analyses [140].
The general maternal administration of heparin in subsequent
pregnancies to women with RM without confirmed thrombophilia
is not indicated because of the lack of proof of efficacy [141–
143]. There is also no evidence for a beneficial effect of adminis-
tering heparin prior to or during the conception period on the pre-
vention of further miscarriages.
To what extent subgroups of patients (e.g., patients with con-
firmed hereditary thrombophilia) actually benefit from the ad-
ministration of heparin in subsequent pregnancies requires fur-
ther studies, such as the currently recruiting, multinational ALIFE2
trial [144]. At present, the general administration of heparin out-
side clinical studies for the indication “prevention of miscarriage”
alone is not indicated, even in thrombophilic women with RM (in
whom APS has not been confirmed) [132,145].hereditary thrombophilia.
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Consensus-based Recommendation 3-8.E35
Expert consensus Level of consensus ++
Thromboprophylaxis for maternal indication should be given during preg-
nancy to women with RM and an increased risk of thromboembolic events.
Consensus-based Recommendation 3-9.E39
Expert consensus Level of consensus ++
Treatment with acetylsalicylic acid with or without additional heparin to
prevent miscarriage is not recommended in women with idiopathic RM.3.8.2.2 Acetylsalicylic acid (ASA)
The use of ASA in pregnancy to prevent miscarriage represents an
off-label use. The administration of ASA in low doses starting in
the 1st trimester of pregnancy reduces the risk of placenta-asso-
ciated complications in late pregnancy [146], although it has not
been possible to confirm any protective effect on the rate of mis-
carriages. The prospective randomized ALIFE trial in women with
idiopathic RM reported that administration of aspirin prior to con-
ception (80mg/day) did not reduce the rate of miscarriages com-
pared to placebo [138]. A systematic Cochrane meta-analysis
found no benefit from the prophylactic administration of ASA in
women with idiopathic RM (RR 0.94; 95% CI: 0.80–1.11) [147].
This also applies to the administration of aspirin prior to concep-
tion [148].Consensus-based Recommendation 3-8.E36
Expert consensus Level of consensus +++
Acetylsalicylic acid therapy to prevent miscarriage is not recommended for
women with RM.3.8.3 Monitoring during pregnancy – D dimersConsensus-based Recommendation 3-8.E37
Expert consensus Level of consensus +++
Monitoring of plasma coagulation markers (D dimers, prothrombin frag-
ments, etc.) during pregnancy is not recommended in women with RM.
Determination of these markers must not be used as an indication to ini-
tiate therapy to prevent miscarriage.
Consensus-based Recommendation 3-9.E40
Expert consensus Level of consensus ++
Treatment with natural micronized progesterone in the first trimester of
pregnancy to prevent miscarriage is not recommended for women with
idiopathic RM.3.9 Idiopathic RM
3.9.1 Diagnosis of idiopathic RM
Idiopathic RM is present if the criteria for a diagnosis of RM are
met, and genetic, anatomical, endocrine, established immuno-
logical and hemostatic factors have been ruled out. The percent-
age of idiopathic RM in the total population of women with RM is
high and amounts to 50–75% [2]. The percentage of live births for
women with idiopathic RM who did not receive treatment is 35–
85% [138,149].Consensus-based Recommendation 3-9.E38
Expert consensus Level of consensus +++
The term “idiopathic RM” is only used if the diagnostic workup described in
this guideline is carried out and no cause of RM has been found.
Toth B et al. Recurrent Miscarriage: Diagnostic… Geburtsh Frauenheilk 2018; 78: 364–3813.9.2 Therapy for idiopathic RM
A Cochrane meta-analysis of nine randomized studies which in-
cluded 1228 women with idiopathic RM who had had at least
two spontaneous miscarriages found no statistically significant ef-
fect of ASA with/without heparin on the LBR compared to placebo
[147]. A randomized study of 364 women with idiopathic RM
found that ASA administration had no impact on LBR compared
to ASA and nadroparin or placebo [138]. Another meta-analysis
of six randomized studies of 907 women with idiopathic RM also
found no improvement in live birth rates following the administra-
tion of ASA and heparin [147].A meta-analysis, published in 2017, of 10 randomized studies
of 1586 women with idiopathic RM reported a positive effect fol-
lowing therapy with progestogens in the first trimester of preg-
nancy, both in terms of the rate of miscarriages (RR 0.72; 95% CI:
0.53–0.97) and the rate of live births (RR 1.07; 95% CI: 1.02–
1.15). Synthetic progestogens, but not natural progesterone,
were associated with a lower risk of recurrent miscarriage [150].
Synthetic progestogens can therefore be administered to women
with idiopathic RM in the first trimester of pregnancy to prevent
miscarriage. However, the optimal time for administration and
the optimal dosage of the progestin are not yet clear.
In the PROMISE trial, a total of 836 women with idiopathic RM
were randomized to receive either placebo or 400mg micronized
progesterone applied by vaginal suppository [151]. Treatment
was initiated soon after positive urinary pregnancy test and con-
tinued up to and including the 12th week of gestation. The LBR
was the same in both study arms (63 and 66%, respectively). How-
ever, a randomized study of 700 women with RM carried out in
Egypt reported significantly higher live birth rates compared to
placebo (91 vs. 77%) for 2 × 400mg progesterone administered
intravaginally, starting in the luteal phase [152].Consensus-based Recommendation 3-9.E40
Expert consensus Level of consensus ++
Synthetic progestogens can be administered to women with idiopathic RM
in the first trimester of pregnancy to prevent miscarriage.
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GebFra Science | GuidelineThe effect of human chorionic gonadotropin (hCG) in doses of
5000–10000 IE in the first and second trimester of pregnancy was
evaluated in five randomized studies of 596 women with RM, in-
cluding women with idiopathic RM. A Cochrane meta-analysis of
these five studies found that the administration of hCG led to a
significant reduction in the frequency of miscarriage. However,
this positive effect was no longer statistically significant when
the analysis was done without the two methodologically weaker
studies (OR 0.74; 95% CI: 0.44–1.23) [153]. The studies did not
include data on LBR. There was no separate subgroup analysis for
women with idiopathic RM. It is therefore currently not possible to
recommend the administration of hCG to treat women with RM.
Scarpellini et al. carried out a randomized study in 68 women
with RM who had previously had at least 4 consecutive spontane-
ous miscarriages. The women were randomized to receive either
placebo or rh-G‑CSF (1 µg/kg/day) starting on the 6th day after
ovulation [154]. LBR for the active study arm was 83% (29/35)
compared to 48% in the control group (16/33). In a retrospective
cohort study Santjohanser et al. reported on 127 women with RM
(for the purposes of that study, RM was defined as at least 2 spon-
taneous early miscarriages) who had IVF/ICSI [155]. Forty-nine of
the women received either rh-G‑CSF at a dose of 34 million units/
week or 2 × 13 million units/week until the 12th week of gesta-
tion. The LBR was 32% higher following G‑CSF administration
compared to 13–14% for other patient groups. As a number of is-
sues (e.g., the optimal dose) relating to G‑CSF therapy are still un-
resolved, G‑CSF should only be administered in the context of a
clinical study.Consensus-based Recommendation 3-9.E41
Expert consensus Level of consensus ++
With the exception of clinical trials, administration of G‑CSF to prevent
miscarriage is not recommended for women with idiopathic RM.
Consensus-based Recommendation 3-9.E42
Expert consensus Level of consensus +++
Treatment with acetylsalicylic acid with or without additional heparin to
prevent miscarriage is not recommended in women with idiopathic RM.Conflict of Interest376Conflicts of interest are given in long version of the guideline.References
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